Concepedia

Kentaro Yamanaka

KY

Statistics

Publications

35

Citations

2.3K

H-Index

25

Active since

1996

Affiliations

Astellas Pharma (Japan)(Current)

The University of Tokyo

National Rehabilitation Center for Persons with Disabilities

Japan Graduate School of Education University

Showa Women's University

Kentaro Yamanaka is an author at Astellas Pharma (Japan) specializing in survivin inhibition, oncology, and medicine.

ORCID

Publications per year

1996–2018

35

Publications

35

YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts

Takahito Nakahara, Masahiro Takeuchi, Isao Kinoyama et al. · Cancer Research · 2007 · 506 citations

, , +17

Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

Takahito Nakahara, Aya Kita, Kentaro Yamanaka et al. · Cancer Science · 2010 · 165 citations

, , +14

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines

Tsutomu Iwasa, Isamu Okamoto, Minoru Suzuki et al. · Clinical Cancer Research · 2008 · 152 citations

, , +15

Quantitative elasticity evaluation by contact resonance in an atomic force microscope

Kentaro Yamanaka, Shizuka Nakano · Applied Physics A · 1998 · 137 citations

, , +16

Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models

Kentaro Yamanaka, Takahito Nakahara, Tomohiro Yamauchi et al. · Clinical Cancer Research · 2011 · 111 citations

, , +17

1–5 of 35